MX2021003910A - Acido ribonucleico bicatenario que inhibe la expresion de c5 de complemento. - Google Patents

Acido ribonucleico bicatenario que inhibe la expresion de c5 de complemento.

Info

Publication number
MX2021003910A
MX2021003910A MX2021003910A MX2021003910A MX2021003910A MX 2021003910 A MX2021003910 A MX 2021003910A MX 2021003910 A MX2021003910 A MX 2021003910A MX 2021003910 A MX2021003910 A MX 2021003910A MX 2021003910 A MX2021003910 A MX 2021003910A
Authority
MX
Mexico
Prior art keywords
double
ribonucleic acid
complement
stranded ribonucleic
inhibiting expression
Prior art date
Application number
MX2021003910A
Other languages
English (en)
Inventor
Yoshinori Takahashi
Yuta Suzuki
Sotaro Motoi
Kazuhiro Tahara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2021003910A publication Critical patent/MX2021003910A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Cosmetics (AREA)
  • Dc Digital Transmission (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se proporciona un ácido ribonucleico bicatenario que comprende una combinación de hebra codificante y hebra no codificante, en donde la combinación de la hebra codificante y la hebra no codificante se selecciona entre el grupo que consiste en las combinaciones: SEC. ID NO: 159 y 160, SEC. ID NO: 141 y 142, SEC. ID NO: 143 y 144, SEC. ID NO: 145 y 146, SEC. ID NO: 147 y 148 y SEC. ID NO: 153 y 154.
MX2021003910A 2018-10-26 2019-10-24 Acido ribonucleico bicatenario que inhibe la expresion de c5 de complemento. MX2021003910A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018201777 2018-10-26
US16/354,916 US10526603B1 (en) 2018-10-26 2019-03-15 Double-stranded ribonucleic acid capable of suppressing expression of complement C5
PCT/JP2019/041783 WO2020085456A1 (ja) 2018-10-26 2019-10-24 補体ｃ５の発現を抑制する二本鎖リボ核酸

Publications (1)

Publication Number Publication Date
MX2021003910A true MX2021003910A (es) 2021-06-04

Family

ID=69058781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003910A MX2021003910A (es) 2018-10-26 2019-10-24 Acido ribonucleico bicatenario que inhibe la expresion de c5 de complemento.

Country Status (20)

Country Link
US (1) US10526603B1 (es)
EP (1) EP3871680B1 (es)
JP (1) JP6725776B1 (es)
KR (1) KR20210086608A (es)
CN (1) CN112771163B (es)
AR (1) AR116832A1 (es)
AU (1) AU2019367536A1 (es)
BR (1) BR112021006520A2 (es)
CA (1) CA3115249A1 (es)
CL (2) CL2021000826A1 (es)
CO (1) CO2021004029A2 (es)
IL (1) IL281902B (es)
JO (1) JOP20210066A1 (es)
MX (1) MX2021003910A (es)
PE (1) PE20210811A1 (es)
PH (1) PH12021550736A1 (es)
SG (1) SG11202102881PA (es)
TW (2) TWI718717B (es)
WO (1) WO2020085456A1 (es)
ZA (1) ZA202102104B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220122608A (ko) * 2019-12-26 2022-09-02 에자이 알앤드디 매니지먼트 가부시키가이샤 보체 c5의 발현을 저해하는 이중 가닥 리보핵산을 함유하는 약제학적 조성물
JP6918197B2 (ja) * 2019-12-26 2021-08-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂質複合体を含む医薬組成物及び脂質ナノ粒子を含む医薬組成物
WO2021154941A1 (en) * 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
WO2023245126A2 (en) * 2022-06-15 2023-12-21 Sirnaomics, Inc. Products and compositions
WO2024169908A1 (zh) * 2023-02-17 2024-08-22 苏州时安生物技术有限公司 一种调节补体C5表达的siRNA、其缀合物和药物组合物及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904654C (en) 2013-03-14 2023-12-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
US9873669B2 (en) 2014-01-09 2018-01-23 Eisai R&D Management Co., Ltd. Cationic lipid
EP3194596A1 (en) * 2014-09-16 2017-07-26 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
JP6592458B2 (ja) 2014-12-26 2019-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 カチオン性脂質
US10036017B2 (en) 2015-02-17 2018-07-31 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
EP3307316A1 (en) * 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
JP2019518028A (ja) * 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
SG11201808928YA (en) 2016-06-24 2018-11-29 Eisai R&D Man Co Ltd Cationic lipid

Also Published As

Publication number Publication date
WO2020085456A1 (ja) 2020-04-30
JOP20210066A1 (ar) 2023-01-30
JP6725776B1 (ja) 2020-07-22
CL2023001965A1 (es) 2023-12-15
IL281902B (en) 2022-09-01
IL281902A (en) 2021-05-31
CN112771163A (zh) 2021-05-07
EP3871680B1 (en) 2024-03-20
KR20210086608A (ko) 2021-07-08
PE20210811A1 (es) 2021-04-28
JPWO2020085456A1 (ja) 2021-02-15
BR112021006520A2 (pt) 2021-07-06
SG11202102881PA (en) 2021-04-29
EP3871680A1 (en) 2021-09-01
AR116832A1 (es) 2021-06-16
CN112771163B (zh) 2024-07-12
TW202031269A (zh) 2020-09-01
PH12021550736A1 (en) 2021-10-25
AU2019367536A1 (en) 2021-04-29
TW202135833A (zh) 2021-10-01
ZA202102104B (en) 2022-08-31
TWI818225B (zh) 2023-10-11
EP3871680A4 (en) 2022-09-21
TWI718717B (zh) 2021-02-11
US10526603B1 (en) 2020-01-07
CO2021004029A2 (es) 2021-04-30
CL2021000826A1 (es) 2021-09-10
CA3115249A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
PH12021550736A1 (en) Double-stranded ribonucleic acid inhibiting expression of complement c5
MX2024006383A (es) Planta de tomate resistente a tbrfv.
MX2021014206A (es) Oligonucleotidos gapmer modificados y metodos de uso.
PH12020500622A1 (en) 17á-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
NZ733882A (en) Compositions for modulating c9orf72 expression
MY191210A (en) Novel promoter and uses thereof
NZ607870A (en) Lactococcus crispr-cas sequences
NZ724277A (en) Compositions and methods for modulating pkk expression
WO2015148580A3 (en) Una oligomers having reduced off-target effects in gene silencing
MX2021007001A (es) Moleculas inhibidoras de acido nucleico de cadena doble que contienen un tribucle.
MX2023001450A (es) Composiciones y metodos para la inhibicion de la expresion de plp1.
WO2019060469A3 (en) CAS9 STREPTOCOCCUS CANIS AS A GENOMIC ENGINEERING PLATFORM WITH NEW PAM SPECIFICITY
PH12020551995A1 (en) Modulator of apol1 expression
MX2021010301A (es) Composiciones y métodos para el tratamiento de laminopatías.
MX2018001126A (es) Oligonucleotidos terapeuticos.
PH12020551191A1 (en) Oligodendrocyte-specific promoter, mirna specific to plp1 gene, vector including said promoter and/or mirna, and pharmaceutical composition including said vector
WO2020104649A3 (en) Novel rna compositions and methods for inhibiting angptl8
EP4282960A3 (en) Modified lipase and use thereof
PH12021551053A1 (en) Modulators of irf5 expression
MX2017001927A (es) Plantas de tomate que permiten el establecimiento de los acaros.
AR083445A1 (es) siARN CONTRA LA FIBROSIS
MX2019006153A (es) Arnip quimicamente modificado.
WO2018231034A3 (ko) 암의 예방 또는 치료용 약학적 조성물
MX2022002689A (es) Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2).
WO2010091878A3 (en) Means for inhibiting the expression of opa1